GlassScriptPhysician profile
Deepanshu Jain
NPI 1215377247
$15,950.90
in general payments reported to CMS, 2019-2025
20 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,679 · 2020: $6,626 · 2021: $1,015 · 2022: $454 · 2023: $858 · 2024: $167 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $675 · Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $675.19 |
| Food and Beverage | $501.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12,515.75 | 2019-2021 | |
| Abbvie INC. | $714.11 | 2019-2023 | |
| Ovesco Endoscopy USA, INC. | $675.19 | 2023 | |
| Olympus Corporation of The Americas | $538.55 | 2019-2020 | |
| Medtronic, INC. | $451.95 | 2022-2025 | Gi Genius, Prodigi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.45 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.56 | 2020-2022 | |
| 3-D Matrix, INC. | $143.22 | 2024 | |
| Celgene Corporation | $121.12 | 2021-2022 | |
| Janssen Biotech, INC. | $82.85 | 2020-2022 | |
| Redhill Biopharma INC. | $76.87 | 2021-2022 | |
| Braintree Laboratories, INC. | $43.62 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $30.71 | 2021 | |
| Conmed Corporation | $24.00 | 2024 | Conmed Biliary |
| Regeneron Healthcare Solutions, INC. | $19.28 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $17.14 | 2021 | |
| Merck Sharp & Dohme LLC | $17.11 | 2022 | |
| Olympus America INC. | $15.84 | 2023 | Endoclot Phs |
| Ferring Pharmaceuticals INC. | $13.66 | 2020 | |
| Intercept Pharmaceuticals, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepanshu Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.